

# World Journal of *Hepatology*

*World J Hepatol* 2024 November 27; 16(11): 1216-1364



**EDITORIAL**

- 1216 Rectal varices vs hemorrhoids-diagnosis and management  
*Majid Z, Yaseen T, Tasneem AA, Luck NH*
- 1219 Is 26S proteasome non-ATPase regulatory subunit 6 a potential molecular target for intrahepatic cholangiocarcinoma?  
*Zhuang YZ, Tong LQ, Sun XY*

**REVIEW**

- 1225 Autoimmune hepatitis: Towards a personalized treatment  
*Costaguta A, Costaguta G, Álvarez F*

**MINIREVIEWS**

- 1243 Current status of drug therapy for alveolar echinococcosis  
*Jing QD, A JD, Liu LX, Fan HN*

**ORIGINAL ARTICLE****Case Control Study**

- 1255 Diagnostic value of tissue plasminogen activator-inhibitor complex in sepsis-induced liver injury: A single-center retrospective case-control study  
*Zhou Y, He LP, Qi YH, Huang Y, Hu BQ, Liu JL, Zeng QB, Song JC*

**Retrospective Cohort Study**

- 1265 Sensitivity of diagnosis of spontaneous bacterial peritonitis is higher with the automated cell count method  
*Acevedo-Haro JG, Mohamed W, Moodley P, Bendall O, Bennett K, Keelty N, Chan S, Waddy S, Hosking J, Thomas W, Tilley R*

**Observational Study**

- 1282 Overexpression of proteasome 26S subunit non-ATPase 6 protein and its clinicopathological significance in intrahepatic cholangiocarcinoma  
*Tang ZQ, Tang YL, Qin K, Li Q, Chen G, Huang YB, Li JJ*

**Basic Study**

- 1290 Non-invasively differentiate non-alcoholic steatohepatitis by visualizing hepatic integrin  $\alpha\beta3$  expression with a targeted molecular imaging modality  
*Huang XQ, Wu L, Xue CY, Rao CY, Fang QQ, Chen Y, Xie C, Rao SX, Chen SY, Li F*
- 1306 Development and validation of biomarkers related to anoikis in liver cirrhosis based on bioinformatics analysis  
*Luo JY, Zheng S, Yang J, Ma C, Ma XY, Wang XX, Fu XN, Mao XZ*

**SYSTEMATIC REVIEWS**

- 1321 Low level of hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in compensated cirrhotic patients

*Lin WC, Lin K, Li MK, Liu X, Huang YF, Wang X, Wu B*

**META-ANALYSIS**

- 1331 Reliability of neutrophil gelatinase-associated lipocalin in detecting acute tubular necrosis in decompensated cirrhosis: Systematic review and meta-analysis

*Agrawal N, Louis-Jean S, Ladiwala Z, Adnani H, Kamal A, Karpman M, Fleisher AS, Singh S*

**CASE REPORT**

- 1339 Liver failure after *Bacillus cereus* food poisoning, an under-recognized entity: A case report

*Chatelangat O, de Lorenzi-Tognon M, Spahr L, Cherkaoui A, Stephan R, Ongaro M, Kaiser L, Goossens N*

- 1348 Pituitary stalk interruption syndrome complicated with liver cirrhosis: A case report

*Chang M, Wang SY, Zhang ZY, Hao HX, Li XG, Li JJ, Xie Y, Li MH*

**LETTER TO THE EDITOR**

- 1356 Rifaximin discontinuation during broad-spectrum antibiotic treatment in critically ill patients with hepatic encephalopathy

*Ridola L, Mari A*

- 1361 Elimination of hepatitis B as a public health threat: Addressing the challenge and taking action

*Ma L, Xing HC*

**ABOUT COVER**

Editorial Board Member of *World Journal of Hepatology*, Farzin Roohvand, PhD, Professor, Senior Scientist, Virology Department, Pasteur Institute of Iran, Tehran 13164, Iran. farzin.roohvand3@gmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Hepatology (WJH, World J Hepatol)* is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJH* mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

**INDEXING/ABSTRACTING**

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (ESCI), Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for *WJH* as 2.5; JIF Quartile: Q3. The *WJH*'s CiteScore for 2023 is 4.1 and Scopus CiteScore rank 2023: Hepatology is 41/82.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Yi-Xuan Cai, Production Department Director: Xiao-Mei Zheng, Cover Editor: Xiang Li.

**NAME OF JOURNAL**

*World Journal of Hepatology*

**ISSN**

ISSN 1948-5182 (online)

**LAUNCH DATE**

October 31, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Koo Jeong Kang

**EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF**

Shuang-Suo Dang

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5182/editorialboard.htm>

**PUBLICATION DATE**

November 27, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**PUBLISHING PARTNER**

Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**POLICY OF CO-AUTHORS**

<https://www.wjgnet.com/bpg/GerInfo/310>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

**PUBLISHING PARTNER'S OFFICIAL WEBSITE**

[http://2yuan.xjtu.edu.cn/Html/Departments/Main/Index\\_21148.html](http://2yuan.xjtu.edu.cn/Html/Departments/Main/Index_21148.html)

## Basic Study

# Non-invasively differentiate non-alcoholic steatohepatitis by visualizing hepatic integrin $\alpha\beta 3$ expression with a targeted molecular imaging modality

Xiao-Quan Huang, Ling Wu, Chun-Yan Xue, Chen-Yi Rao, Qing-Qing Fang, Ying Chen, Cao Xie, Sheng-Xiang Rao, Shi-Yao Chen, Feng Li

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's classification**

**Scientific Quality:** Grade C

**Novelty:** Grade B

**Creativity or Innovation:** Grade B

**Scientific Significance:** Grade B

**P-Reviewer:** Liu XY

**Received:** March 26, 2024

**Revised:** August 27, 2024

**Accepted:** October 20, 2024

**Published online:** November 27, 2024

**Processing time:** 224 Days and 14.5 Hours



**Xiao-Quan Huang, Ling Wu, Chun-Yan Xue, Chen-Yi Rao, Shi-Yao Chen, Feng Li,** Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

**Qing-Qing Fang, Ying Chen, Shi-Yao Chen, Feng Li,** Department of Gastroenterology, Minhang Hospital, Fudan University, Shanghai 201100, China

**Cao Xie,** Department of Pharmacy, Fudan University, Shanghai 200032, China

**Sheng-Xiang Rao,** Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

**Co-first authors:** Xiao-Quan Huang and Ling Wu.

**Corresponding author:** Feng Li, MD, Chief Physician, Research Scientist, Senior Scientist, Staff Physician, Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai 200032, China. [li.feng2@zs-hospital.sh.cn](mailto:li.feng2@zs-hospital.sh.cn)

## Abstract

### BACKGROUND

Non-invasive methods to diagnose non-alcoholic steatohepatitis (NASH), an inflammatory subtype of non-alcoholic fatty liver disease (NAFLD), are currently unavailable.

### AIM

To develop an integrin  $\alpha\beta 3$ -targeted molecular imaging modality to differentiate NASH.

### METHODS

Integrin  $\alpha\beta 3$  expression was assessed in Human LO2 hepatocytes cultured with palmitic and oleic acids (FFA). Hepatic integrin  $\alpha\beta 3$  expression was analyzed in rabbits fed a high-fat diet (HFD) and in rats fed a high-fat, high-carbohydrate diet (HFCD). After synthesis, cyclic arginine-glycine-aspartic acid peptide (cRGD) was labeled with gadolinium (Gd) and used as a contrast agent in magnetic resonance imaging (MRI) performed on mice fed with HFCD.

## RESULTS

Integrin  $\alpha\beta3$  was markedly expressed on FFA-cultured hepatocytes, unlike the control hepatocytes. Hepatic integrin  $\alpha\beta3$  expression significantly increased in both HFD-fed rabbits and HFCD-fed rats as simple fatty liver (FL) progressed to steatohepatitis. The distribution of integrin  $\alpha\beta3$  in the liver of NASH cases largely overlapped with albumin-positive staining areas. In comparison to mice with simple FL, the relative liver MRI-T1 signal value at 60 minutes post-injection of Gd-labeled cRGD was significantly increased in mice with steatohepatitis ( $P < 0.05$ ), showing a positive correlation with the NAFLD activity score ( $r = 0.945$ ;  $P < 0.01$ ). Hepatic integrin  $\alpha\beta3$  expression was significantly upregulated during NASH development, with hepatocytes being the primary cells expressing integrin  $\alpha\beta3$ .

## CONCLUSION

After using Gd-labeled cRGD as a tracer, NASH was successfully distinguished by visualizing hepatic integrin  $\alpha\beta3$  expression with MRI.

**Key Words:** Non-alcoholic steatohepatitis; Cyclic peptides; Magnetic resonance imaging; Non-invasive diagnosis; Hepatic integrin  $\alpha\beta3$

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Early identification of non-alcoholic steatohepatitis (NASH) patients and accurate assessment of non-alcoholic fatty liver disease severity are crucial for improving patient outcomes. Currently, no non-invasive method can replace liver biopsy to accurately discern NASH. Hepatic integrin  $\alpha\beta3$  expression significantly increased as simple fatty liver progressed to steatohepatitis. Inflammatory-injured hepatocytes, which might be the primary cells expressing integrin  $\alpha\beta3$  in steatohepatitis, were identified on the basis of steatosis. Utilizing gadolinium-labeled cyclic arginine-glycine-aspartic acid peptide as a contrast agent, steatohepatitis was successfully differentiated by visualizing hepatic integrin  $\alpha\beta3$  expression using a magnetic resonance imaging modality.

**Citation:** Huang XQ, Wu L, Xue CY, Rao CY, Fang QQ, Chen Y, Xie C, Rao SX, Chen SY, Li F. Non-invasively differentiate non-alcoholic steatohepatitis by visualizing hepatic integrin  $\alpha\beta3$  expression with a targeted molecular imaging modality. *World J Hepatol* 2024; 16(11): 1290-1305

**URL:** <https://www.wjgnet.com/1948-5182/full/v16/i11/1290.htm>

**DOI:** <https://dx.doi.org/10.4254/wjh.v16.i11.1290>

## INTRODUCTION

Currently, non-alcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide and is estimated to affect about 25%-30% of the global population[1]. NAFLD encompasses a spectrum of liver disorders, ranging from simple fatty liver (FL) to non-alcoholic steatohepatitis (NASH), which can ultimately progress to cirrhosis[2]. NASH, an inflammatory subtype of NAFLD, is histologically characterized by hepatic steatosis accompanied by hepatocyte injury (ballooning) and intralobular inflammation, with or without fibrosis[3]. Due to the close association of NAFLD with metabolic disorders such as obesity, hyperlipidemia, and type 2 diabetes, and given the ongoing epidemic of these conditions, the prevalence of NAFLD, along with the proportion of NASH, is projected to continue rising in the coming decade[4]. Compared to the general population and patients with simple FL, a significantly higher proportion of NASH patients can progress to cirrhosis, hepatocellular carcinoma (HCC), and death[4-6]. Consequently, early identification of NASH and accurate assessment of NAFLD severity are crucial to improving patient outcomes.

Over the past two decades, numerous non-invasive methods have been explored to identify NASH among patients with NAFLD. These methods include conventional imaging examinations, imaging-based evaluation approaches such as magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF), serum biomarkers (*e.g.*, cytokeratin 18), and several complex scoring systems composed of clinical and laboratory values. The characteristics of various non-invasive diagnostic methods are summarized in Table 1. While the diagnosis of FL and advanced liver fibrosis, even cirrhosis, can be made using these methods, none can accurately distinguish NASH, and invasive liver biopsy remains the only accepted method for reliably diagnosing NASH[4,6]. However, performing a liver biopsy on every NAFLD patient is neither feasible nor necessary, as the procedure has limitations, including sampling errors that affect diagnostic accuracy and the risk of operative complications such as bleeding, infection, and, rarely, mortality[6,7]. Therefore, there is an urgent need to develop a novel non-invasive method to accurately distinguish NASH and monitor disease progression.

Integrins are transmembrane glycoprotein heterodimeric receptors that primarily mediate adhesion between different cells or between cells and the extracellular matrix. They participate in signal transduction related to cell proliferation, activation, movement, and apoptosis, thereby playing a pivotal role in immune regulation, injury repair, tumor infiltration, and other processes[8-10]. A common feature of integrins is their ability to bind endogenous ligands by

**Table 1 Summary characteristics of different non-invasive methods[31-36]**

Methods			Advantages	Flaws	Patients (n)	AUROC	Sensitivity (%)	Specificity (%)	
Imaging modalities	Quantitative ultrasound biomarkers	Ultrasound attenuation coefficient[31]	Low cost and wide availability; High sensitivity and specificity in grading	The diagnostic performance is affected by the presence of fibrosis.	125 (Excluding liver fibrosis)	S0 vs S1, S2, S3	0.951	82.1	95.5
						S0, S1 vs S2, S3	0.987	94.3	93.9
						S0, S1, S2 vs S3	0.931	94.1	85.5
					Ultrasound-derived fat fraction[32]	Low cost and wide availability; Real-time data collection	High interobserver variability	46	S0 vs S1, S2, S3
	S0, S1 vs S2, S3	0.980							
	CT	Contrast-enhanced CT [33]	Common in clinical practice; Quantify liver fat without additional radiation exposure	Exposes patients to ionizing radiation	1204	Steatosis ≥ 5%	0.669	34.0	94.2
						Steatosis ≥ 10%	0.854		
						Steatosis ≥ 15%	0.962	75.9	95.7
		Non-contrast dual-energy CT[34]	Reliable for detection of moderate steatosis	Influenced by varying contrast bolus and scan timing, cardiac output	128	Right lobe	0.834	57.0	94.0
	Left lobe					0.872	68.0	90.0	
MR-PDFF[35]		It is used as a reference for testing other clinical or biochemical markers	Expensive; availability-limited; unable to assess liver inflammation, ballooning	77	S0 vs S1, S2, S3	0.989	97	100	
					S0, S1 vs S2, S3	0.825	61	90	
					S0, S1, S2 vs S3	0.893	68	91	
Serum biomarkers	Laboratory parameter-based model	NAFLD bridge score [36]	Data availability and cost-effectiveness	Unable to differentiate NASH from simple steatosis with high sensitivity and specificity	422	With and without NAFLD	0.880	95	87

MR-PDFF: Magnetic resonance imaging-estimated proton density fat fraction; AUROC: Area under the receiver operating characteristic curve; CT: Computed tomography; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.

recognizing the amino acid binding motif arginine-glycine-aspartic acid (RGD)[9,11]. Among the 24 known integrin heterodimers, consisting of 18  $\alpha$ -subunit and 8  $\beta$ -subunit variants, integrin  $\alpha v \beta 3$  has been the most studied over the past two decades. Numerous RGD-binding drugs targeting integrin  $\alpha v \beta 3$  have been developed for the treatment of integrin  $\alpha v \beta 3$ -associated diseases[12-14].

In our previous studies, cyclic RGD pentapeptide was prepared and demonstrated to specifically bind to integrin  $\alpha v \beta 3$  on activated hepatic stellate cells both *in vitro* and *in vivo*[15,16]. Additionally, after the synthesized cyclic RGD peptide was directly radiolabeled or used to modify the dendrimer nanoprobe, molecular imaging approaches using single photon emission computed tomography or MRI were developed to non-invasively distinguish the severity of liver fibrosis[15,16]. In this study, hepatic expression of integrin  $\alpha v \beta 3$  was observed in different animal models of NAFLD. Furthermore, after synthesizing cyclic RGD peptides modified with gadolinium (Gd) and using them as an MRI contrast agent, we aimed to develop a molecular imaging modality to distinguish NASH by visualizing hepatic integrin  $\alpha v \beta 3$  expression.

## MATERIALS AND METHODS

### Animals

Eight-week-old male Sprague-Dawley rats, six-week-old male C57BL/6J mice, and four-month-old male New Zealand white rabbits were obtained from the Experimental Animals Department of Zhongshan Hospital, Fudan University (Shanghai, China). All experiments were conducted in accordance with governmental and international guidelines on

animal experimentation. The study was reviewed and approved by the Zhongshan Hospital Institutional Review Board, and all experiments were performed following these guidelines.

### **Synthesis of cyclic RGD peptide and its derivative**

Cyclic RGD (cRGD) peptide [cyclo (Arg-Gly-Asp-D-Tyr-Lys)] was synthesized and labeled with Gd as previously described[15-17]. Briefly, cRGD was initially synthesized using an Fmoc-protected solid-phase peptide synthesis method and subsequently labeled with Gd through 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to form cRGD-DOTA-Gd. The molecular weights of cRGD and cRGD-DOTA-Gd were determined using analytical reverse-phase high-performance liquid chromatography, and their purities were assessed by electrospray ionization mass spectrometry. The Gd<sup>3+</sup> content of cRGD-DOTA-Gd was determined using a Hitachi P-4010 (Tokyo, Japan). Inductively Coupled Plasma Atomic Emission Spectroscopy system.

### **Expression of integrin $\alpha v \beta 3$ in cultured hepatocytes**

Human LO2 hepatocytes (from the Cell Bank of the Chinese Academy of Sciences, Shanghai, China) were cultured in a medium supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin/streptomycin in a 5% CO<sub>2</sub> humidified atmosphere at 37 °C.

Firstly, LO2 cells were cultured in a medium containing 100  $\mu$ mol/L palmitic acid and 200  $\mu$ mol/L oleic acid (FFA) for 24 hours, after which they were stained with Oil-Red O. LO2 cells cultured in medium without FFA served as controls. Secondly, after being fixed with 4% paraformaldehyde and permeabilized with phosphate-buffered saline (PBS) containing 0.1% Triton X-100 and 0.1 mg/mL RNase A when appropriate, the control and FFA-cultured hepatocytes were incubated with primary antibodies against integrin  $\alpha v$  subunit (1:1000, Abmart, T56887) or integrin  $\beta 3$  subunit (1:1000, Abmart, M015908), and albumin (1:1000, Servicebio, GB122080) at 4 °C overnight. Subsequently, these cells were incubated with secondary antibodies, including Alexa Fluor 594-conjugated immunoglobulin (Ig) G (1:200, Jackson, PA, United States) and Alexa Fluor 488-conjugated IgG (1:200, Jackson, PA, United States), counterstained with 6-diamidino-2-phenylindole at room temperature for 1 hour, and then photographed with a fluorescence microscope (Olympus, Japan). The message RNA (mRNA) levels and protein amounts of integrin  $\alpha v$  and integrin  $\beta 3$  subunits were then determined in the control and FFA-cultured hepatocytes as described below.

### **Rabbit model of NAFLD induced by high-fat diet**

Rabbits were fed a high-fat diet (HFD), which included an additional 20% corn oil in the regular diet containing 3.81% fat, 17.8% protein, and 46.5% carbohydrate (provided by the Experimental Animals Department of Zhongshan Hospital). Based on preliminary experimental results, rabbits fed with HFD for 2, 6, and 8 months were selected for further experiments [referred to as HFD-2 months (M), HFD-6M, and HFD-8M rabbits, respectively]. Rabbits fed with a regular diet for 8 months served as the control group ( $n = 10$  for each group).

### **Murine models of NAFLD induced by high-fat high-carbohydrate diet**

Sprague-Dawley rats and C57BL/6J mice were fed a high-fat high-carbohydrate diet (HFCD), which contained 60 kcal% fats, 20 kcal% proteins, and 20 kcal% carbohydrates (D12492, SHUYISHUER bio, Changzhou, China), along with high fructose/glucose (55% fructose and 45% glucose, Sigma, United States) in drinking water at a concentration of 42 g/L. Two months, four months, or six months after the treatment, treated rats and mice were used for further experiments (referred to as HFCD-2M, HFCD-4M, and HFCD-6M rats or mice, respectively). Rats and mice fed with a regular diet for 6 months served as the control group.

### **Histological analysis**

After fixation in neutralized formalin for 48 hours, liver sections were stained with hematoxylin and eosin. Liver sections from rats and mice were stained with Masson, while those from rabbits were stained with Sirius red to assess the degree of liver fibrosis. Additionally, Oil-Red O staining was used to evaluate the degree of hepatic steatosis in frozen liver sections. The severity of NAFLD was semi-quantitatively scored according to the NAFLD activity score, which included steatosis (0-3), lobular inflammation (0-3), and ballooning (0-2)[18]. A score greater than 4 was defined as NASH.

### **Immunohistochemistry analysis**

Hepatic expression of integrin  $\alpha v \beta 3$  was initially assessed in control and HFD-fed rabbits using immunohistochemistry analysis as previously described[17]. Briefly, mouse monoclonal anti-integrin  $\beta 3$  antibody (1:400 in blocking solution, Millipore, Massachusetts, United States, MAB1974) and biotin-conjugated goat polyclonal anti-mouse IgG (1:100 in blocking solution, Abcam, ab6788) were used as the primary and secondary antibodies, respectively. Ten fields (400  $\times$  magnification) from each liver section were randomly selected and recorded, and the integrin  $\beta 3$  subunit positive-staining areas were quantified using NIN Image 1.62 software. The percentage of positive-staining areas in each section was then calculated.

### **Quantitative real-time polymerase chain reaction analysis**

Hepatic mRNA levels of integrin  $\alpha v$  and integrin  $\beta 3$  subunits in control and HFCD-fed rats were quantified using quantitative real-time polymerase chain reaction analysis as described previously[15]. The forward primers for integrin  $\alpha v$  and integrin  $\beta 3$  subunits were CGAAGCCTTAGCAAGACTGTCCTG and GACTCGGACTGGACTGGC-TACTAC, respectively. The reverse primers were CAGTTGAGTCCAGCCTTCATCGG and ACTTCTCGCAGGT-GTCTCCATAGG, respectively. GAPDH was used as the reference, with forward and reverse primers TCCCTCAAGAT-

TGTCAGCAA and AGATCCACAACGGATACATT, respectively. The relative expression of integrin  $\alpha v$  and integrin  $\beta 3$  subunits mRNA was analyzed using the comparative cycle threshold method. Additionally, total RNA was extracted from control and FFA-cultured LO2 hepatocytes, and the mRNA expression levels of integrin  $\alpha v$  and integrin  $\beta 3$  subunits in these cells were also determined.

### Western blot assay

The protein amounts of integrin  $\alpha v$  and integrin  $\beta 3$  subunits in the livers of control and HFCD-fed rats were determined by western blot analysis. Additionally, protein was extracted from control and FFA-cultured LO2 hepatocytes, and the protein expression levels of integrin  $\alpha v$  and integrin  $\beta 3$  subunits in these cells were analyzed.  $\beta$ -tubulin was used as the reference. After chemiluminescent signals were generated and detected on radiographic film, the relative expression of integrin  $\alpha v$  and integrin  $\beta 3$  subunits was quantified by scanning densitometry analysis.

### Immunofluorescent co-localization of integrin $\alpha v \beta 3$ in various hepatic cells

Immunofluorescent staining was performed to reveal the co-localization of integrin  $\beta 3$  subunits with markers of various hepatic cells, including albumin (hepatocytes),  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA) (activated hepatic stellate cell), cluster of differentiation (CD) 31 (hepatic sinusoidal endothelial cells), CD68 (macrophages), and CD163 (Kupffer cells), in liver sections of control and HFCD-fed rats as previously described[15]. Primary antibodies against integrin  $\beta 3$  subunit (1:500; Abmart), monoclonal anti-albumin (1:500; Servicebio), monoclonal anti-SMA (1:500, Servicebio, GB111364), monoclonal anti-CD31 (1:500, Servicebio, GB11063-1), monoclonal anti-CD68 (1:500, Servicebio, GB11067), and monoclonal anti-CD163 (1:500, Servicebio, GB11340-1) were used. Secondary antibodies included Alexa Fluor 594-conjugated IgG (1:200, Jackson) and Alexa Fluor 488-conjugated IgG (1:200, Jackson). Multicolored fluorescent staining of liver sections was analyzed, and 10 randomly selected amplifying fields (400  $\times$ ) in each section were assessed using Image-Pro Plus version 6.0.0.260. The percentage of integrin  $\beta 3$  subunit-stained green area in each section and the ratio of the merged yellow color area to the total integrin  $\beta 3$  subunit-stained area in each section were calculated.

### In vivo MRI studies

MRI was performed in mice using a Biospec 70/20 MRI scanner (7.0 T, Bruker, Germany) to assess the accumulation of cRGD-DOTA-Gd in livers after cRGD-DOTA-Gd was injected intravenously at a dose of 0.05 mmol/kg [ $Gd^{3+}$ ] in a total of 0.25 mL PBS solution in the control and HFCD-fed mice, as described previously[16]. Briefly, dynamic T1-weighted MRIs of the liver were collected before and at 30, 60, 90, and 120 minutes after cRGD-DOTA-Gd injection. Cross-sectional images of the liver were acquired using a fast low-angle shot sequence and processed with Weasis software version 3.8.1. The signal intensity of the hepatic region [T1 (liver)] was measured, and the muscle signal intensity [T1 (muscle)] from the region of interest in the same section was used to normalize the hepatic signal intensity. The relative hepatic signal intensity was denoted as T1 (liver)/T1 (muscle). The relative hepatic signal intensity before (T0) and at different time points (Tt) after the injection of cRGD-DOTA-Gd were calculated, and the relative liver MRI-T1 signal value at a specific time point post-injection was determined by subtracting T0 from Tt.

### Statistical analysis

Data were presented as the mean  $\pm$  SD and analyzed by a one-way analysis of variance followed by the least significant difference test. Statistical product and service solutions 24.0 statistical software (Chicago, United States) was used, and a *P* value of  $< 0.05$  was considered statistically significant.

## RESULTS

### Properties of cRGD and its derivative




Cyclic peptides (cRGD) were prepared and labeled with Gd (cRGD-DOTA-Gd). The molecular weights of cRGD and cRGD-DOTA-Gd were 623 and 1362 Da, respectively, and their purities exceeded 95%. The  $Gd^{3+}$  content in cRGD-DOTA-Gd was 8.1%.


### Expression of integrin $\alpha v \beta 3$ in hepatocytes in vitro

After LO2 hepatocytes were cultured with FFA for 24 hours, the accumulation of fat droplets was observed in most cells through Oil-Red O staining (Figure 1A), indicating the development of hepatocyte steatosis. Integrin  $\alpha v \beta 3$  was expressed on FFA-cultured hepatocytes as shown by immunofluorescent staining, but not on the control hepatocytes (Figure 1B and C). Compared to the control cells, the mRNA expression levels and protein amounts of integrin  $\alpha v$  and integrin  $\beta 3$  subunits were significantly increased in FFA-cultured hepatocytes (Figure 1B-F, *P*  $< 0.05$  for all comparisons).

### Expression of integrin $\alpha v \beta 3$ in livers of rabbits with NAFLD

The expression of integrin  $\alpha v \beta 3$  in NAFLD livers was initially observed in HFD-fed rabbits. After 2 months of HFD feeding, lipid accumulation in hepatocytes was observed, indicating the development of hepatic steatosis. With prolonged HFD feeding for 6 and 8 months, hepatic steatosis worsened, and hepatocyte ballooning became prominent, accompanied by inflammatory cell infiltration in hepatic lobules and the formation of perisinusoidal fibrosis, even bridge fibrosis (Figure 2A). The NAFLD activity score was significantly higher in HFD-6M and HFD-8M rabbits compared to control and HFD-2M rabbits (Figure 2B, *P*  $< 0.05$  for all comparisons). After immunohistochemical staining of hepatic





**Figure 1 Expression of integrin  $\alpha v \beta 3$  in cultured hepatocytes.** Human LO2 hepatocytes were cultured with the medium containing 100  $\mu\text{mol/L}$  palmitate acid and 200  $\mu\text{mol/L}$  oleic acid (FFA) for 24 hours, and the cells cultured in the medium without FFA served as the control. A: Representative micrographs of the control and FFA-cultured hepatocytes after stained with Oil-Red O. Images were taken at original magnification (200 $\times$ ), scale bars = 20  $\mu\text{m}$ ; B and C: Representative fluorescent images of the control (B) and FFA-cultured (C) hepatocytes after separately stained with integrin  $\alpha v$  and  $\beta 3$  subunits antibody (green color) and counterstained with albumin antibody (red color). 6-diamidino-2-phenylindole was used for nuclei staining. The merged images show the yellow color area by overlaying images of the counterstaining. Images were taken at original magnification (400 $\times$ ), scale bars = 100  $\mu\text{m}$ ; D: Comparison of the message RNA levels of integrin  $\alpha v$  and  $\beta 3$  subunits in the control and FFA-cultured hepatocytes. The message RNA levels of integrin  $\alpha v$  and  $\beta 3$  subunit were determined by quantitative real-time polymerase chain reaction analysis; E and F: Comparison of the protein amounts of integrin  $\alpha v$  and  $\beta 3$  subunits in the control and FFA-cultured hepatocytes. The protein amounts of integrin  $\alpha v$  and  $\beta 3$  subunits were analyzed by western-blot assay, and  $\beta$ -Tubulin was used as the reference. All experiments were undertaken in triplicates. In all panels, data are expressed in means  $\pm$  SD. FFA: Oleic acid; DAPI: 6-diamidino-2-phenylindole.

slices for integrin  $\beta 3$  subunits, abundant positive-staining areas were observed in HFD-6M and HFD-8M rabbits (Figure 2A). The percentage of integrin  $\beta 3$  subunit positive-staining areas in the livers of HFD-6M and HFD-8M rabbits ( $22.83 \pm 4.93$  and  $37.22 \pm 2.88$ , respectively) was significantly higher than in control ( $2.68 \pm 0.97$ ) and HFD-2M rabbits ( $10.82 \pm 1.48$ ) (Figure 2C,  $P < 0.05$  for all comparisons). These results indicated that hepatic expression of integrin  $\alpha v \beta 3$  increased consistently with the progression of NAFLD, with a significant increase observed when the condition progressed to NASH.

### Expression of integrin $\alpha v \beta 3$ in livers of rats with NAFLD


As shown in Figure 3A, after rats were fed with HFCD, massive fat droplets accumulated in hepatocytes, which was most prominent in HFCD-6M rats. As hepatic steatosis worsened, hepatocyte ballooning and inflammatory cell infiltration became more pronounced in hepatic lobules after 4 months of HFCD feeding. When the HFCD feeding was prolonged to 6 months, perisinusoidal fibrosis was observed in hepatic lobules. Compared to control rats ( $1.17 \pm 0.41$ ) and HFCD-2M rats ( $1.83 \pm 0.75$ ), the NAFLD activity score of hepatic tissue was significantly increased in HFCD-4M and HFCD-6M rats ( $4.00 \pm 0.89$  and  $6.83 \pm 0.75$ , respectively), with the highest score in HFCD-6M rats (Figure 3B,  $P < 0.05$  for all comparisons). These results indicated that simple FL developed in rats after 2 months of HFCD feeding, progressed to steatohepatitis after 4 months, and further advanced to NASH with liver fibrosis after 6 months.

Hepatic integrin  $\alpha v \beta 3$  expression during the development and progression of NAFLD was further assessed in HFCD-fed rats. Compared to control and HFCD-2M rats, hepatic mRNA expression levels of integrin  $\alpha v$  and integrin  $\beta 3$  subunits were significantly increased after 4 months of HFCD feeding, reaching the highest levels in HFCD-6M rats (Figure 3C,  $P < 0.05$  for all comparisons). Additionally, the protein amounts of integrin  $\alpha v$  and integrin  $\beta 3$  subunits in hepatic tissue gradually increased in HFCD-fed rats, with levels significantly higher than those in control rats (Figure 3D-F,  $P < 0.05$  for all comparisons). These results indicated that hepatic integrin  $\alpha v \beta 3$  expression progressively increased with the development and progression of NAFLD.

### Localization of integrin $\alpha v \beta 3$ in livers with NAFLD

To identify the principal cells expressing integrin  $\alpha v \beta 3$  in livers with NAFLD, double immunofluorescent staining was performed to visualize the co-localization of the integrin  $\beta 3$  subunit with albumin,  $\alpha$ -SMA, CD31, CD68, and CD163 in control and HFCD-fed rats. Integrin  $\alpha v \beta 3$  expression was negligible in the livers of control rats, as no integrin  $\beta 3$  subunit positive-staining (green) areas were found in the liver slices (Figure 4A). In contrast, increasing integrin  $\beta 3$  subunit positive-staining areas were observed in the liver slices of HFCD-fed rats, particularly in HFCD-6M rats (Figure 4B-D). The percentage of integrin  $\beta 3$  subunit positive-staining areas in the liver slices of HFCD-4M and HFCD-6M rats was significantly higher than in control and HFCD-2M rats (Figure 4E,  $P < 0.05$  for all comparisons).

Additionally, in the livers of HFCD-6M rats, the positive staining of the integrin  $\beta 3$  subunit (green) extensively overlapped (yellow) with albumin staining (red) and showed minimal overlap with  $\alpha$ -SMA, CD31, CD68, or CD163 staining (Figure 4D). The ratio of the overlapped area of integrin  $\beta 3$  subunit staining with albumin positive-staining was significantly higher than the overlapped staining with other cellular markers (Figure 4F,  $P < 0.05$  for all comparisons).




**Figure 2** Expression of integrin  $\alpha v \beta 3$  in livers of rabbits with non-alcoholic fatty liver disease. Non-alcoholic fatty liver disease was induced in rabbits by high-fat diet (HFD) for 2, 6, and 8 months (referred to as HFD-2M, 6M and 8M), and rabbits fed with regular diet for 8 months served as the control group ( $n = 6$  per group). A: Representative micrographs of hepatic histology stained with hematoxylin-eosin staining (200  $\times$ ), Sirius red (100  $\times$ ), and immunohistochemistry for integrin  $\beta 3$  subunit (400  $\times$ ). In immunohistochemistry staining images, the brown areas indicated integrin  $\beta 3$  subunit positive staining, scale bars = 50  $\mu\text{m}$ ; B: Comparison of non-alcoholic fatty liver disease activity score in the control and HFD-fed rabbits; C: Comparison of the percentage of integrin  $\beta 3$  subunit positive-staining area in liver sections of the control and HFD-fed rabbits. For semi-quantitative analysis of hepatic integrin  $\alpha v \beta 3$  expression level, 10 fields were randomly selected and recorded from each section stained with immunohistochemistry for integrin  $\beta 3$  subunit. Then integrin  $\beta 3$  subunit positive-staining area was measured, and the percentages of the positive-staining area in liver sections were compared. In all panels, data are expressed in means  $\pm$  SD. IHC: Immunohistochemistry; HE: Hematoxylin-eosin staining; CTRL: Normal control group; M: Month; NS: Not significant; NAFLD: Non-alcoholic fatty liver disease.

These findings suggest that hepatic expression of integrin  $\alpha v \beta 3$  markedly increased as simple FL progressed to steatohepatitis, with hepatocytes being the primary cells expressing integrin  $\alpha v \beta 3$  in livers with NASH.

### Imaging the progression of NAFLD by MRI *in vivo*

After being fed with HFCD for 6 months, the rats became so obese that no suitable coil was available for MRI examination. Therefore, mice were used for *in vivo* MRI experiments. After the mice were fed with HFCD, similar histopathological findings were observed in their livers: Simple FL developed in HFCD-2M mice and progressed to steatohepatitis in HFCD-4M and HFCD-6M mice (Figure 5A).

A dynamic T1-weighted MRI approach was employed to assess the deposition of cRGD-DOTA-Gd in the livers after the radiotracers were intravenously injected in control and HFCD-fed mice. As shown in Figure 5B, there was no significant change in hepatic signal intensity in control mice before and up to 120 minutes after cRGD-DOTA-Gd injection. In contrast, in HFCD-6M mice, compared to pre-injection levels, the hepatic signal was markedly intensified at 60 minutes post-injection of cRGD-DOTA-Gd and then gradually decreased. Compared to control mice, the relative liver MRI-T1 signal value at 60 minutes post-injection of cRGD-DOTA-Gd was significantly increased in mice fed with HFCD



**Figure 3** Expression of integrin  $\alpha v\beta 3$  in livers of rats with non-alcoholic fatty liver disease. Non-alcoholic fatty liver disease was induced in rats by

high-fat high-carbohydrate diet (HFCD) for 2, 4, and 6 months (referred to as HFCD-2M, 4M and 6M), and rats fed with regular diet for 6 months served as the control group ( $n = 6$  per group). A: Representative micrographs of hepatic histology stained with H&E (200 ×), Masson (100 ×), and Oil-red O (200 ×), scale bars = 50 μm; B: Comparison of non-alcoholic fatty liver disease activity score in the control and HFCD-fed rats; C: Comparison of hepatic integrin  $\alpha v \beta 3$  message RNA level in the control and HFCD-fed rats. Hepatic message RNA levels of integrin  $\alpha v$  and  $\beta 3$  subunits were respectively determined by quantitative real-time polymerase chain reaction analysis; D-F: Comparison of the protein amounts of integrin  $\alpha v \beta 3$  in livers of the control and HFCD-fed rats. The protein amounts of integrin  $\alpha v$  and  $\beta 3$  subunits were analyzed by western-blot assay, and  $\beta$ -Tubulin was used as the reference. In all panels, data are expressed in means  $\pm$  SD. HE: Hematoxylin-eosin staining; CTRL: Normal control group; M: Month; NS: Not significant; NAFLD: Non-alcoholic fatty liver disease.

for 4 months, with the highest values observed in HFCD-6M mice (Figure 5C,  $P < 0.05$  for all comparisons). Furthermore, the relative hepatic MRI-T1 signal value at 60 minutes post-injection of cRGD-DOTA-Gd showed a strong positive correlation with the NAFLD activity score in HFCD-fed mice ( $r = 0.945$ ,  $P < 0.01$ , Figure 5D).

## DISCUSSION


To date, the development of a non-invasive method that can accurately diagnose NASH and determine the disease severity of NAFLD, thereby replacing the need for liver biopsy, remains one of the urgent unmet needs in the NASH field [4]. Compared to other conventional imaging modalities, such as ultrasound and computed tomography, MRI offers the highest spatial resolution for soft tissues and is considered the most sensitive modality for evaluating hepatic steatosis [19]. While these imaging modalities can also detect advanced liver fibrosis and cirrhosis, none can accurately distinguish NASH. Recently, several MRI-based imaging modalities, such as MRI-PDFF and magnetic resonance elastography (MRE), have been developed for NAFLD diagnosis. MRI-PDFF is currently the gold standard for diagnosing and quantifying hepatic steatosis, showing excellent accuracy in detecting dynamic changes in steatosis, but it fails to provide information on steatohepatitis and fibrosis [20,21]. Conversely, MRE is recognized as the most accurate imaging modality for diagnosing liver fibrosis in NAFLD, primarily by measuring elastic shear wave propagation through liver parenchyma [22, 23]. However, MRE cannot accurately discriminate NASH without significant fibrosis, and more importantly, the presence of inflammation in the liver with NASH negatively impacts its accuracy in diagnosing fibrosis. Therefore, no current non-invasive imaging method can accurately discern NASH.


Many animal models are currently available for basic and translational research on NAFLD, primarily grouped into two categories: specific gene knockout models and special diet-induced models. Compared to gene knockout NAFLD models, the animal models induced by special diets, particularly high-fat ( $\pm$  high-carbohydrate) diets, more comprehensively mimic the spectrum of metabolic and histological features of human NAFLD [24]. In the present study, the HFD-induced NAFLD rabbit model was initially used to observe the expression of integrin  $\alpha v \beta 3$  in the liver with NAFLD. However, significant individual variability in hepatic histopathological manifestations was found in HFD-fed rabbits. Therefore, HFCD-induced NAFLD murine models were used to further assess hepatic integrin  $\alpha v \beta 3$  expression and conduct *in vivo* MRI examinations. With prolonged HFCD feeding, hepatic steatosis developed and progressed to steatohepatitis in most rats and mice, as demonstrated histologically.


In our previous study, it was found that integrin  $\alpha v \beta 3$  in fibrotic livers was primarily expressed on activated hepatic stellate cells, and its expression level strongly correlated with the degree of liver fibrosis, while it was scarcely expressed on hepatocytes [15,25]. Additionally, Rokugawa *et al* [26] recently reported quantitatively evaluating hepatic integrin  $\alpha v \beta 3$  expressed on activated hepatic stellate cells using positron emission tomography imaging in rats with NASH [26,27]. However, in the present study, hepatocytes - not activated hepatic stellate cells - were found to be the primary cells expressing integrin  $\alpha v \beta 3$  in NASH livers. In the *in vivo* study, hepatic expression of integrin  $\alpha v \beta 3$  was significantly increased in NASH livers, with no expression in normal livers and mild expression in livers with simple FL. More importantly, most integrin  $\alpha v \beta 3$  was found to be expressed on hepatocytes in NASH livers, as demonstrated by double immunofluorescent staining for integrin  $\alpha v \beta 3$  and markers of various hepatic cells. In the *in vitro* study, integrin  $\alpha v \beta 3$  was markedly expressed on hepatocytes cultured with palmitic acid and FFA, but not on normal control hepatocytes. It has been demonstrated that hepatocytes develop not only steatosis, but also inflammatory injury and apoptosis after being cultured with palmitic acid and FFA [28]. These results indicate that on the basis of steatosis, hepatocytes injured by inflammation express abundant integrin  $\alpha v \beta 3$  in NASH livers. Additionally, based on these results, we speculate that integrin  $\alpha v \beta 3$  might play a role in the pathogenesis of NASH, which needs to be further elucidated in future studies.

In this study, hepatic integrin  $\alpha v \beta 3$  expression significantly increased as simple FL progressed to steatohepatitis, with or without fibrosis, which correlated with the increased NAFLD activity score. Therefore, we aimed to visualize hepatic integrin  $\alpha v \beta 3$  expression during the development and progression of NAFLD using an MRI-based molecular imaging modality. After Gd-labeled cRGD, targeted to integrin  $\alpha v \beta 3$ , was injected, the hepatic signal markedly intensified at 60 minutes post-injection compared to pre-injection levels, and the relative liver MRI-T1 signal value at 60 minutes post-injection was significantly increased in mice with NASH compared to control mice and those with simple FL, showing a linear correlation with the NAFLD activity score. These results indicated that the binding amount of Gd-labeled cRGD in the liver significantly increased secondary to elevated hepatic integrin  $\alpha v \beta 3$  expression during the development of NASH. Thus, NASH was successfully differentiated from simple FL in NAFLD by visualizing hepatic integrin  $\alpha v \beta 3$  expression with the targeted molecular imaging modality.


Recently, it has been found that long-term outcomes, including overall mortality in patients with NAFLD, are strongly associated with the severity of liver fibrosis but not with the NAFLD activity score [29]. However, non-NASH NAFLD








**Figure 4** Immunofluorescent co-localization of integrin  $\alpha\beta 3$  and the markers of various hepatic cells including  $\alpha$ -smooth muscle actin, cluster of differentiation 31, cluster of differentiation 68 or cluster of differentiation 163 in livers of the control and high-fat high-carbohydrate diet-fed rats. Representative fluorescent images of integrin  $\beta 3$  subunit (green color) and albumin,  $\alpha$ -smooth muscle actin, cluster of differentiation (CD) 31, CD68 and CD163 (red color) in liver sections, which were separately stained with specific first antibodies and visualized by second antibodies, and counterstained with 6-diamidino-2-phenylindole for nuclei staining. The merged images show the yellow color area by overlaying images of the counterstaining, and amplified images corresponding to the indicated areas in boxes are present. Images were recorded at original magnification (400  $\times$ ), scale bars = 100  $\mu\text{m}$ . A: Control; B: High-fat high-carbohydrate diet (HFCD)-2M; C: HFCD-4M; D: HFCD-6M rats; E: Comparison of the percentage of integrin  $\beta 3$  subunit positive-staining area in liver sections of the control and HFCD-fed rats. Ten fields were randomly selected and recorded from each section. Then integrin  $\beta 3$  positive-staining area was measured, and the percentages of the positive-staining area in liver sections were compared; F: Comparison of the ratio of the overlapped yellow area to integrin  $\beta 3$  subunit positive-staining green area in liver sections of HFCD-6M rats. Ten fields were randomly selected and recorded from each section. Then integrin  $\beta 3$  subunit positive-staining area and the area of integrin  $\beta 3$  subunit positive-staining overlapped with hepatic cellular markers positive-staining were respectively measured, and the ratios were compared. In all panels, data are expressed in means  $\pm$  SD. DAPI: 6-diamidino-2-phenylindole; CTRL: Normal control group; M: Month; CD: Cluster of differentiation;  $\alpha$ SMA:  $\alpha$ -smooth muscle actin.





**Figure 5** Imaging non-alcoholic fatty liver disease using a magnetic resonance imaging modality with cyclic arginine-glycine-aspartic acid peptides labeled with gadolinium through 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid as a tracer in mice. Non-alcoholic fatty liver disease was induced in mice by high-fat high-carbohydrate diet (HFCD) for 2, 4, and 6 months (referred to as HFCD-2M, 4M and 6M), and mice fed with regular diet for 6 months served as the control group ( $n = 3$  per group). A: Representative micrographs of hepatic histology stained with hematoxylin-eosin staining (200 ×), Masson (100 ×), and Oil-red O (200 ×), scale bars = 50 μm; B: Representative hepatic T1-weighted magnetic resonance imaging (MRI) of the control and HFCD-6M mice prior to and at 30, 60, 90 and 120 minutes after cyclic arginine-glycine-aspartic acid (cRGD)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-gadolinium (Gd) injection; C: Comparison of the relative liver MRI-T1 signal value in the control and HFCD-fed mice 60 minutes after cRGD-DOTA-Gd injection. Data are expressed in means ± SD; D: Correlation of the relative liver MRI-T1 signal value at 60 minutes post-injection of cRGD-DOTA-Gd with non-alcoholic fatty liver disease activity score was assessed. HE: Hematoxylin-eosin staining; CTRL: Normal control group; M: Month; NS: Not significant; NAFLD: Non-alcoholic fatty liver disease; HFCD: High-fat high-carbohydrate diet; MRI: Magnetic resonance imaging.

seldom progresses to significant fibrosis, indicating that steatohepatitis is a cornerstone in the development and progression of liver fibrosis in NAFLD[4-6]. More importantly, HCC has been found to develop in NASH patients without liver cirrhosis[30]. Consequently, it is essential to discern NASH early and regularly monitor the progression of NAFLD, but invasive liver biopsy, the only currently accepted method for diagnosing NASH, fails to achieve this goal. In contrast, non-invasive molecular imaging modalities could potentially be utilized for routine screening and regular follow-up of NASH in the NAFLD population. Over the past decades, numerous molecular imaging modalities have been developed for diagnosing tumors and their metastases, especially those with integrin  $\alpha\beta3$ -positive expression[14]. Furthermore, in our previous studies, two molecular imaging modalities were explored to diagnose liver fibrosis by visualizing hepatic  $\alpha\beta3$  expression in the development and progression of fibrosis[15,16]. All these developments will aid in promoting the clinical application of integrin  $\alpha\beta3$ -targeted molecular imaging modalities in NASH diagnosis.

However, the availability and cost-effectiveness of MRI are still worth considering. There is no doubt that MRI is more expensive than ultrasound or computed tomography-based imaging modalities and tends to be more time-consuming. Nevertheless, the reliability of MRI is widely accepted, and other non-invasive methods are often compared with MRI-based methods like MRI-PDFF, which are limited in assessing inflammation, to evaluate their potential in clinical applications. In this study, we developed an RGD-based MRI contrast agent to differentiate steatohepatitis by visualizing hepatic integrin  $\alpha\beta3$  expression, which could counteract the interference of inflammation in MRI detection. This approach holds promise for future development and use.

## CONCLUSION

In conclusion, this study demonstrated that hepatic integrin  $\alpha\beta3$  expression significantly increased as simple FL progressed to NASH. Hepatocytes, injured by inflammation on the basis of hepatic steatosis, were the primary cells expressing integrin  $\alpha\beta3$  in NASH livers. After cyclic RGD peptides were labeled with Gd and used as a contrast agent, NASH was successfully distinguished by visualizing hepatic integrin  $\alpha\beta3$  expression with an MRI modality.

## ACKNOWLEDGEMENTS

The authors would like to acknowledge Pang ZY (Shanghai East Hospital) for valuable assistance with fluorescence microscopy and MRI analysis.

## FOOTNOTES

**Author contributions:** Li F and Huang XQ designed the research study; Huang XQ, Wu L, Xue CY, Rao CY, Fang QQ and Chen Y performed the research; Huang XQ, Wu L, Xue CY and Rao CY collected and analyzed data; Xie C and Rao SX conducted animal imaging and analysis; Wu L and Huang XQ wrote the manuscript; Li F, Huang XQ, Wu L, Chen SY revised the manuscript; All authors have read and approved the final manuscript.

**Supported by** the National Natural Science Foundation of China, No. 81670513; and Young Scientists Fund of the National Natural Science Foundation of China, No. 81900511.

**Institutional review board statement:** This study does not involve human subject research.

**Institutional animal care and use committee statement:** This study was performed in line with the Declaration of Helsinki and the ethical approval was obtained from the Institutional Ethical Committee of Animal Experimentation, Zhongshan Hospital affiliated to Fudan University.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Data sharing statement:** Data will be made available upon reasonable request.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country of origin:** China

**ORCID number:** Xiao-Quan Huang 0000-0002-8752-4899; Ling Wu 0000-0001-6574-6493; Chun-Yan Xue 0000-0001-6567-8451; Chen-Yi Rao 0000-0002-0785-6931; Qing-Qing Fang 0000-0002-2694-1357; Ying Chen 0000-0003-4016-8011; Sheng-Xiang Rao 0000-0001-7722-8327; Shi-Yao Chen 0000-0002-0873-9198; Feng Li 0000-0002-3529-9626.

**S-Editor:** Fan M

**L-Editor:** A

**P-Editor:** Xu ZH

## REFERENCES

- 1 **Younossi Z**, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. *Hepatology* 2019; **69**: 2672-2682 [PMID: 30179269 DOI: 10.1002/hep.30251]
- 2 **Pouwels S**, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. *BMC Endocr Disord* 2022; **22**: 63 [PMID: 35287643 DOI: 10.1186/s12902-022-00980-1]
- 3 **Chalasan N**, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2018; **67**: 328-357 [PMID: 28714183 DOI: 10.1002/hep.29367]
- 4 **Cotter TG**, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. *Gastroenterology* 2020; **158**: 1851-1864 [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052]
- 5 **Rinella ME**, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology* 2023; **77**: 1797-1835 [PMID: 36727674 DOI: 10.1097/HEP.000000000000323]
- 6 **Sheka AC**, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. *JAMA* 2020; **323**: 1175-1183 [PMID: 32207804 DOI: 10.1001/jama.2020.2298]
- 7 **Ajmera V**, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. *Mol Metab* 2021; **50**: 101167 [PMID: 33460786 DOI: 10.1016/j.molmet.2021.101167]
- 8 **Xu S**, Zhang T, Cao Z, Zhong W, Zhang C, Li H, Song J. Integrin- $\alpha$ 9 $\beta$ 1 as a Novel Therapeutic Target for Refractory Diseases: Recent Progress and Insights. *Front Immunol* 2021; **12**: 638400 [PMID: 33790909 DOI: 10.3389/fimmu.2021.638400]

- 9 **Slack RJ**, Macdonald SJF, Roper JA, Jenkins RG, Hatley RJD. Emerging therapeutic opportunities for integrin inhibitors. *Nat Rev Drug Discov* 2022; **21**: 60-78 [PMID: 34535788 DOI: 10.1038/s41573-021-00284-4]
- 10 **De Marco R**, Tolomelli A, Juaristi E, Gentilucci L. Integrin Ligands with  $\alpha/\beta$ -Hybrid Peptide Structure: Design, Bioactivity, and Conformational Aspects. *Med Res Rev* 2016; **36**: 389-424 [PMID: 26777675 DOI: 10.1002/med.21383]
- 11 **Ruoslahti E**. My scientific journey to and through extracellular matrix. *Matrix Biol* 2024; **133**: 57-63 [PMID: 39151809 DOI: 10.1016/j.matbio.2024.08.003]
- 12 **Sani S**, Messe M, Fuchs Q, Pierrelvelcin M, Laquerriere P, Entz-Werle N, Reita D, Etienne-Selloum N, Bruban V, Choulier L, Martin S, Dontenwill M. Biological Relevance of RGD-Integrin Subtype-Specific Ligands in Cancer. *Chembiochem* 2021; **22**: 1151-1160 [PMID: 33140906 DOI: 10.1002/cbic.202000626]
- 13 **Bhatwadekar AD**, Kansara V, Luo Q, Ciulla T. Anti-integrin therapy for retinovascular diseases. *Expert Opin Investig Drugs* 2020; **29**: 935-945 [PMID: 32657172 DOI: 10.1080/13543784.2020.1795639]
- 14 **Li ZH**, Zhou Y, Ding YX, Guo QL, Zhao L. Roles of integrin in tumor development and the target inhibitors. *Chin J Nat Med* 2019; **17**: 241-251 [PMID: 31076128 DOI: 10.1016/S1875-5364(19)30028-7]
- 15 **Li F**, Song Z, Li Q, Wu J, Wang J, Xie C, Tu C, Wang J, Huang X, Lu W. Molecular imaging of hepatic stellate cell activity by visualization of hepatic integrin  $\alpha v \beta 3$  expression with SPECT in rat. *Hepatology* 2011; **54**: 1020-1030 [PMID: 21618580 DOI: 10.1002/hep.24467]
- 16 **Li F**, Yan H, Wang J, Li C, Wu J, Wu S, Rao S, Gao X, Jin Q. Non-invasively differentiating extent of liver fibrosis by visualizing hepatic integrin  $\alpha v \beta 3$  expression with an MRI modality in mice. *Biomaterials* 2016; **102**: 162-174 [PMID: 27341269 DOI: 10.1016/j.biomaterials.2016.06.026]
- 17 **Wu L**, Huang XQ, Li N, Xie C, Rao SX, Chen SY, Li F. A magnetic resonance imaging modality for non-invasively distinguishing progression of liver fibrosis by visualizing hepatic platelet-derived growth factor receptor-beta expression in mice. *J Gastroenterol Hepatol* 2021; **36**: 3448-3456 [PMID: 34278598 DOI: 10.1111/jgh.15628]
- 18 **Kleiner DE**, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; **41**: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701]
- 19 **Selvaraj EA**, Mózes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, Levick CK, Young LAJ, Palaniyappan N, Liu CH, Aithal GP, Romero-Gómez M, Brosnan MJ, Tuthill TA, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. *J Hepatol* 2021; **75**: 770-785 [PMID: 33991635 DOI: 10.1016/j.jhep.2021.04.044]
- 20 **Caussy C**, Reeder SB, Sirlin CB, Loomba R. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. *Hepatology* 2018; **68**: 763-772 [PMID: 29356032 DOI: 10.1002/hep.29797]
- 21 **Xia T**, Du M, Li H, Wang Y, Zha J, Wu T, Ju S. Association between Liver MRI Proton Density Fat Fraction and Liver Disease Risk. *Radiology* 2023; **309**: e231007 [PMID: 37874242 DOI: 10.1148/radiol.231007]
- 22 **Castera L**, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2019; **156**: 1264-1281.e4 [PMID: 30660725 DOI: 10.1053/j.gastro.2018.12.036]
- 23 **Ozturk A**, Olson MC, Samir AE, Venkatesh SK. Liver fibrosis assessment: MR and US elastography. *Abdom Radiol (NY)* 2022; **47**: 3037-3050 [PMID: 34687329 DOI: 10.1007/s00261-021-03269-4]
- 24 **Jahn D**, Kircher S, Hermanns HM, Geier A. Animal models of NAFLD from a hepatologist's point of view. *Biochim Biophys Acta Mol Basis Dis* 2019; **1865**: 943-953 [PMID: 29990551 DOI: 10.1016/j.bbadis.2018.06.023]
- 25 **Zhong L**, Zhao J, Huang L, Liu Y, Pang X, Zhan K, Li S, Xue Q, Pan X, Deng L. Runx2 activates hepatic stellate cells to promote liver fibrosis via transcriptionally regulating Itgav expression. *Clin Transl Med* 2023; **13**: e1316 [PMID: 37403784 DOI: 10.1002/ctm2.1316]
- 26 **Rokugawa T**, Konishi H, Ito M, Iimori H, Nagai R, Shimosegawa E, Hatazawa J, Abe K. Evaluation of hepatic integrin  $\alpha v \beta 3$  expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET. *EJNMMI Res* 2018; **8**: 40 [PMID: 29855729 DOI: 10.1186/s13550-018-0394-4]
- 27 **Hiroshima S**, Rokugawa T, Ito M, Iimori H, Morita I, Maeda H, Fujisawa K, Matsunaga K, Shimosegawa E, Abe K. Quantitative evaluation of hepatic integrin  $\alpha(v)\beta(3)$  expression by positron emission tomography imaging using (18)F-FPP-RGD(2) in rats with non-alcoholic steatohepatitis. *EJNMMI Res* 2020; **10**: 118 [PMID: 33026561 DOI: 10.1186/s13550-020-00704-3]
- 28 **Zhang M**, Bai X, Du Q, Xu J, Wang D, Chen L, Dong K, Chen Z, Yang J. The Different Mechanisms of Lipid Accumulation in Hepatocytes Induced by Oleic Acid/Palmitic Acid and High-Fat Diet. *Molecules* 2023; **28** [PMID: 37764494 DOI: 10.3390/molecules28186714]
- 29 **Ekstedt M**, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hulcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* 2015; **61**: 1547-1554 [PMID: 25125077 DOI: 10.1002/hep.27368]
- 30 **Shah PA**, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: The growing challenge. *Hepatology* 2023; **77**: 323-338 [PMID: 35478412 DOI: 10.1002/hep.32542]
- 31 **Gao J**, Zapata I, Chen J, Erpelding TN, Adamson C, Park D. Quantitative Ultrasound Biomarkers to Assess Nonalcoholic Fatty Liver Disease. *J Ultrasound Med* 2023; **42**: 1675-1688 [PMID: 36744595 DOI: 10.1002/jum.16185]
- 32 **Zalcman M**, Barth RA, Rubesova E. Real-time ultrasound-derived fat fraction in pediatric population: feasibility validation with MR-PDFF. *Pediatr Radiol* 2023; **53**: 2466-2475 [PMID: 37667050 DOI: 10.1007/s00247-023-05752-0]
- 33 **Pickhardt PJ**, Blake GM, Graffy PM, Sandfort V, Elton DC, Perez AA, Summers RM. Liver Steatosis Categorization on Contrast-Enhanced CT Using a Fully Automated Deep Learning Volumetric Segmentation Tool: Evaluation in 1204 Healthy Adults Using Unenhanced CT as a Reference Standard. *AJR Am J Roentgenol* 2021; **217**: 359-367 [PMID: 32936018 DOI: 10.2214/AJR.20.24415]
- 34 **Zhang PP**, Choi HH, Ohliger MA. Detection of fatty liver using virtual non-contrast dual-energy CT. *Abdom Radiol (NY)* 2022; **47**: 2046-2056 [PMID: 35306577 DOI: 10.1007/s00261-022-03482-9]
- 35 **Tang A**, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, Gamst AC, Middleton M, Brunt EM, Loomba R, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. *Radiology* 2013; **267**: 422-431 [PMID: 23382291 DOI: 10.1148/radiol.12120896]
- 36 **Yip TC**, Ma AJ, Wong VW, Tse YK, Chan HL, Yuen PC, Wong GL. Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. *Aliment Pharmacol Ther* 2017; **46**: 447-456 [PMID: 28585725 DOI: 10.1111/apt.14172]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

